
Combining over 1,000 human antibodies, GIGA-2339 aims to achieve viral clearance and activate the immune system, offering a potential solution where current therapies fall short of providing a cure.
Senior Vice President at Grifols and head of GigaGen.

Combining over 1,000 human antibodies, GIGA-2339 aims to achieve viral clearance and activate the immune system, offering a potential solution where current therapies fall short of providing a cure.

Carter Keller discusses the company's recent $135.2 million contract with BARDA to develop recombinant polyclonal antibody therapies targeting botulinum neurotoxins and an unspecified biothreat, highlighting their innovative approach to address emerging health threats.

Following FDA approval, GigaGen's therapy enters Phase 1 clinical trials as the first recombinant human polyclonal therapy for hepatitis B.

Published: August 12th 2024 | Updated: August 12th 2024

Published: November 25th 2024 | Updated:

Published: October 4th 2024 | Updated: